Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
52 participants
OBSERVATIONAL
2019-08-02
2019-10-25
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
FuRST 2.0 Cognitive Pre-Testing
NCT02881931
Wearable Sensors for Quantitative Assessment of Motor Impairment in Huntington's Disease Huntington's Disease
NCT03599076
Feasibility and Acceptability of Implementing a Clinic-based Physical Activity Coaching Intervention in People With Premanifest and Early Stage HD
NCT03306888
A Pre-Cellular Therapy Observational Study in Early Huntington's Disease
NCT01937923
Development of the Virtual Unified Huntington's Disease Rating Scale
NCT05748288
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
OTHER
CROSS_SECTIONAL
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Premanifest HDGEC participants
FuRST 2.0
Round 2 of cognitive pre-testing for a new functional rating scale
Early-manifest HDGEC participants
FuRST 2.0
Round 2 of cognitive pre-testing for a new functional rating scale
Companions of Premanifest HDGEC
FuRST 2.0
Round 2 of cognitive pre-testing for a new functional rating scale
Companions of Early-manifest
FuRST 2.0
Round 2 of cognitive pre-testing for a new functional rating scale
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
FuRST 2.0
Round 2 of cognitive pre-testing for a new functional rating scale
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* At least 18 years of age
* Fluent in English and had his/her primary education in English
* Able and willing to provide critical feedback (per site PI or site PI's designee discretion)
* Willing and able to provide written informed consent
* Cytosine, Adenine, Guanine (CAG) length ≥ 40
* Disease burden score (DBS) ≥ 250
* Diagnostic confidence level (DCL) ≤ 3
* Identified as an active participant in Enroll-HD (participants who have completed their last onsite Enroll-HD visit within approximately 15 months)
* At least 18 years of age
* Fluent in English and had his/her primary education in English
* Able and willing to provide critical feedback (per site PI or site PI's designee discretion)
* Willing and able to provide written informed consent
* CAG length ≥ 36
* DCL= 4
* Total Functional Capacity (TFC) ≥11
* At least 18 years of age
* Fluent in English and had his/her primary education in English
* In his/her opinion, has sufficient interaction and knowledge of the HDGEC participant's capabilities and daily activities
* Is acceptable to the HDGEC participant and the site PI or site PI's designee
* Willing and able to provide written informed consent
Exclusion Criteria
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Dr. Glenn T. Stebbins (Rush University Medical Center )
UNKNOWN
Dr. Nancy LaPelle
UNKNOWN
CHDI Foundation, Inc.
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Rocky Mountain Movement Disorders Center, P.C.
Englewood, Colorado, United States
Hereditary Neurological Disease Centre, Inc.
Wichita, Kansas, United States
Columbia University
New York, New York, United States
Centre for Movement Disorders (Neuropharm Consulting)
Toronto, Ontario, Canada
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
C-000918-3
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.